Advertisement

Topics

Immunomedics Enters Agreement with University of Wisconsin to Expand Sacituzumab Govitecan into Prostate Cancer

09:42 EST 12 Jan 2018 | Speciality Pharma Journal

MORRIS PLAINS, N.J., Jan. 11, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced a collaboration with the Carbone Cancer Center at the University of Wisconsin, through Immunomedics entering an agreement with The Prostate Cancer Clinical Trials Consortium (PCCTC), to investigate Immunomedics’ lead antibody-drug conjugate (ADC) product candidate, sacituzumab govitecan, in an investigator-sponsored …

Original Article: Immunomedics Enters Agreement with University of Wisconsin to Expand Sacituzumab Govitecan into Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "Immunomedics Enters Agreement with University of Wisconsin to Expand Sacituzumab Govitecan into Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...